The content is available as a PDF (29.1 KB).
Acknowledgments
The competing interests statement in the original version of this article omitted information relating to patents for Ernest E. Moore and Hunter B. Moore. The updated competing interests statement reads “E.E.M. currently receives research support from Haemonetics, Instrumentation Laboratory, Stago, Hemosonics, Diapharma, Prytime, Humacyte and Genentech; he is a co-founder of ThromboTherapeutics; he is listed as inventor on the following patents relating to blood coagulation or fibrinolysis (including assays): WO-2016073668-A1 (assignee: The Regents Of The University Of Colorado; status: published); US-9354243-B2 (assignee: Haemonetics Corporation, The Regents Of The University Of Colorado, A Body Corporate; status: granted); WO-2019014595-A1 (assignee: Thrombo Therapeutics, Inc.; status: published); EP-3215634-A1 (assignee: The Regents of the University of Colorado; status: published); EP-3303943-A1 (assignee: The Regents of The University of Colorado, A Body Corporate; status: published); WO-2021158799-A1 (assignee: The Regents Of The University Of Colorado, A Body Corporate; status: published); US-2020208194-A1 (assignee: Massachusetts Institute Of Technology, University Of Colorado; status: published). H.B.M. receives research support from Haemonetics and Instrumentation Laboratory; he is a co-founder of ThromboTherapeutics; he is listed as inventor on the following patents relating to blood coagulation or fibrinolysis (including assays): WO-2016073668-A1 (assignee: The Regents Of The University Of Colorado; status: published); WO-2019014595-A1 (assignee: Thrombo Therapeutics, Inc.; status: published); EP-3215634-A1 (assignee: The Regents of the University of Colorado; status: published); US-2020208194-A1 (assignee: Massachusetts Institute Of Technology, University Of Colorado; status: published). M.D.N. receives research support from Haemonetics, Janssen Pharmaceuticals, Accriva Diagnostics and Instrumentation Laboratory; he serves on the Scientific Advisory Board with equity stake in Haima Therapeutics.
Footnotes
All other authors declare no competing interests.